12 Nov Complix to Present its Cell Penetrating Alphabodies Acting on Important Intracellular Targets at PEGS Europe 2018

Posted at 08:00h in Events by

Hasselt, November 12, 2018 – Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodies (CPABs) announces that its Chief Scientific Officer, Dr Yvonne McGrath, will be presenting recent developments on CPABs against intracellular targets at the 10th Annual PEGS Europe Meeting (Protein and Antibody Engineering Summit) in Lisbon Portugal, November 12-16.

In her presentation Dr McGrath will provide an update on Complix’ recent progress with respect to CAPBs acting on important intracellular cancer targets. In particular Dr McGrath will be showing results obtained with CPABs targeting the enhanceosome of the Wnt pathway, a key pathway involved in development of cancer and other major diseases.

Details of the talk are as follows:

  • Title: “Cell Penetrating Alphabodies to Access Undruggable Intracellular Targets”
  • Session: “Engineering Antibodies”
  • Time: November 14 at 09:05 CET

 

About Complix

Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics active against intracellular targets that play a key role in life threatening diseases, including cancer.

CPABs act with great precision and high affinity on targets that are considered intractable by current drug formats, such as antibodies or small chemicals. Complix is developing a growing pipeline of CPABs primarily focusing on intracellular oncogenic targets that play a key role in cancer development and progression. The Company is currently running multiple in-house CPAB programs based on selection from a diverse collection of undruggable targets, two of which are being developed in a $280 million research partnership with Merck & Co.

Complix believes that, thanks to their unique capacity to address a broad universe of intractable targets, CPABs represent an entirely novel class of therapeutics that have the potential to significantly improve treatment outcomes for cancer patients.

Complix has established a strong intellectual property position protecting the Alphabody platform and its emerging product portfolio through the filing of multiple broad patent applications. Since its foundation in 2008 Complix has raised more than €27 million through several rounds of equity financing from a syndicate of leading life sciences investors.

 

Contacts

Complix NV
Dr. Yvonne McGrath, CSO
Tel. +32 9 261 69 40
www.complix.com

Print page